cisplatin + 5-fluorouracil

Standard of care therapy-Latin American Cooperative Oncology Group-penile carcinoma refers to the chemotherapy regimen used as the control or backbone treatment in clinical trials conducted by the Latin American Cooperative Oncology Group (LACOG) for advanced penile squamous cell carcinoma, such as the Phase II LACOG 0218 trial. This regimen typically consists of cisplatin (70 mg/m² IV on Day 1) or carboplatin (AUC 5 IV on Day 1) combined with 5-fluorouracil (1000 mg/m²/day via continuous intravenous infusion on Days 1-4), administered every three weeks for up to six cycles. Cisplatin and carboplatin are platinum-based antineoplastic agents that form covalent DNA adducts and cross-links, leading to apoptosis. 5-fluorouracil is a pyrimidine analog that acts as an antimetabolite, primarily by inhibiting thymidylate synthase, which is essential for DNA synthesis and repair. This combination is a standard systemic approach for various squamous cell carcinomas.

Other names

PF regimenCF regimencisplatin + 5-FUcarboplatin + 5-FU